Registrations
Welcome address
Moderators: A. Nikolaidi (GR), F.I. Dimitrakopoulos (GR)
12.00-12.20 Precision and Personalized Medicine in Gynecological Cancers M. Liontos (GR)
12.20-12.40 Molecular classification of endometrial cancer E. Kavoura (GR)
12.40-13.00 Therapeutic Strategies for Cervical Malignancies G. Tsironis (CY)
13.00-13.20 First- and Second-Line Therapies in Endometrial Cancer A. Koliadou (SE)
13.20-13.40 Clinical Implications of PARP Inhibitor in Ovarian Cancer Treatment: State of the Art and Future Perspectives S. Linardopoulos (UK)
13.40-14.00 Discussion
Moderators: T. Mamounas (US), G. Fotopoulos (CY)
16.30-16.50 Personalized or massive screening S. Douvetzemis (GR)
16.50-17.10 HR-Positive Breast Cancer adjuvant: Selecting Therapy after adjuvant chemotherapy A. Matikas (SE)
17.10-17.30 Gene signatures in decision making A. Valachis (SE)
17.30-17.40 Discussion
Hall I: Oncology pipeline: GI vision E. Anastasopoulou (GR)
Moderators: I. Athanasiadis (GR), V. Karantza (US)
18.00-18.20 ER, HER2-Positive Metastatic Breast Cancer: Where are We Headed? V. Kaklamanis (US)
18.20-18.40 The future prospective: Immunotherapy V. Karantza (US)
18.40-19.00 Systemic therapy beyond immunotherapy E. Andreopoulou (US)
19.00-19.15 Discussion
Moderators: Ν. Κarachaliou (DE), A. Kotsakis (GR)
Detecting Cancer with Liquid Biopsy. Current state and future hope N. Papadopoulos (US)
Moderators: A. Bamias (GR), Ch. Charalambous (CY)
08.30-08.50 Managing RCC in 2023-Overview of current evidence P. Tsantoulis (CH)
08.50-09.10 Case 1 Patient with newly diagnosed stage III ccRCC following nephrectomy K. Koutsoukos (GR)
09.10-09.30 Case 2 Patient with newly diagnosed mccRCC (Poor/intermediate risk) Ν. Androulakis (GR)
09.30-09.50 Case 3 Patient with mccRCC following progression on first-line Therapy V. Bozionelou (GR)
09.50-10.10 Case 4 Patient with papillary mRCC N. Pistalmatzian (GR)
10.10-10.30 Discussion
Moderators: S. Baritaki (GR), A. Kyriazoglou (GR)
11.00-11.20 Immune Responses Triggered by Abrogation of BRCA1/2 Tumour Suppressors Y. Markou (CY)
11.20-11.40 Next frontiers in immunotherapy in solid tumors D. Papadatos - Pastos (UK)
11.40-12.00 Neoadjuvant vs adjuvant immunotherapy A. Digklia (SUI)
12.00-12.15 Discussion
Moderators: A. Koumarianou (GR), G. Tzimas (GR)
PART 1: DIAGNOSTIC APPROACH
12.15-12.25 Biomarkers and conventional imaging Ch. Toumbanakis (UK)
12.25-12.35 Molecular imaging I. Karfis (BE)
PART 2: THERAPEUTIC STRATEGY
12.35-12.45 Established and emerging options for symptoms’ and tumour growth control Ch. Toumbanakis (UK)
12.45-12.55 The role of Peptide Receptor Radionuclide Therapy I. Karfis (BE)
12.50-13.00 Discussion
Hall 1 Εmerging biomarkers in cancer G. Vasmatzis (US), V. Anagnostou (US)
Hall 2 Artificial Intelligence N. Papanikolaou (PT), K. Marias (GR)
Hall 3 Real World Data/Pragmatic Trials D. Papamichael (CY), Th. Foukakis (SE)
Moderators: I. Souglakos (GR), D. Papamichael (CY)
14.30-14.50 Features and susceptibility to environmentally induced colorectal carcinogenesis/Early Colorectal Cancer M. Giannakis (US)
14.50-15.10 Neoadjuvant Treatment Approaches for Stage II-III Rectal Cancer N. Gouvas (GR)
15.10-15.30 Personalised tt in mCRC D. Papamichael (CY)
15.30-15.50 Native immunity & dysbiosis in Colorectal Cancer I. Messaritakis (CY)
15.50-16.00 Discussion
Moderators: M. Nikolaou (GR), N. Tsoukalas (GR), Th. Tegos (GR)
16.00-16.20 Challenging clinical cases across the prostate cancer disease spectrum A. Patrikidou (FR)
16.20-16.40 Challenging Cases in Breast Cancer A. Constantinidou (CY)
16.40-17.00 A case of Myxoïd Liposarcoma D. Tzanis (FR)
Medical Education opportunities in United States P. Savvides (US)
Moderators: V. Georgoulias (GR), I. Boukovinas (GR)
18.30-19.00 TBD A. Tsimberidou (US)
19.00-19.30 T cell therapy and tumor vasculature - reciprocal modulation G. Coukos (SUI)
19.30-20.00 Critical appraisal of WCLC 2023 K. Leventakos (US)
Moderators: S. Karagiannis (UK), A. Dimou (US)
20.00-20.20 IgE class antibody immunotherapy for solid tumours S. Karagiannis (UK)
20.20 -20.40 Biomarkers on immunotherapy response in urothelial carcinoma P. Grivas (US)
20.40- 21.00 Invariant NKT cell platform for treatment of blood cancers A. Karadimitris (UK)
Moderators: G. Nasioulas (GR), F.I. Dimitrakopoulos (GR)
Tumor Board: P. Christopoulos (DE), G. Vasmatzis (US), V. Anagnostou (US),
K. Linos (US), P. Savvides (US), A. Saetta (GR), Ch. Christopoulos (FR)
Moderators: A. Christopoulou (GR), M. Rovithi (GR)
10.00-10.20 The surgical approach of hepatobiliary Tumors A. Prahalias (UK)
10.20-10.40 Local treatments K. Katsanos (GR)
10.40-11.00 Systemic treatments I. Boukovinas (GR)
Moderators: A. Zygogianni (GR), I. Georgakopoulos (GR)
Radiation Therapy, DNA Damage, and Immune Response H. Gkika (DE)